The safety and pharmacodynamic results in the multiple-dose trial must be interpreted in light of the high dose levels (2040 mg oral semaglutide) and the relatively fast initial dose escalation in this trial compared with the phase III trials, where dose levels of 314 mg oral semaglutide are investigated and a slower initial dose escalation is used to minimise gastrointestinal adverse effects
More confident in your own skin
These cascades are termed here as 'go pathways'
[49] Sharretts, J., Galescu, O., Gomatam, S., Andraca-Carrera, E., Hampp, C., & Yanoff, L
What's the difference between 503A and 503B compounding pharmacies